Zollinger‑Ellison Syndrome (Type II) – A Comprehensive Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare neuroendocrine disorder characterized by one or more gastrin‑producing tumors (gastrinomas) that cause excessive gastric acid secretion. The “type II” designation refers to the subset of patients whose gastrinomas occur as part of the hereditary multiple endocrine neoplasia type 1 (MEN 1) syndrome.

Key facts

• Overall prevalence of ZES: ≈ 1 case per 1 million people worldwide.^[1]
• Approximately 20‑30 % of ZES patients have MEN 1 (type II).^[2]
• Typical age at diagnosis: 30‑50 years for sporadic (type I) cases; 20‑40 years for MEN 1‑related (type II) cases.
• Both sexes are affected equally, but MEN 1 is slightly more common in men.

Symptoms

Symptoms result from hyperacidic gastric secretions and from the tumor itself. They may be intermittent, making early diagnosis challenging.

Gastro‑intestinal symptoms

• Refractory peptic ulcer disease – ulcers that fail to heal with standard therapy, often multiple and located distal to the duodenum (e.g., jejunal ulcers).
• Abdominal pain – crampy or burning pain, usually related to meals.
• Diarrhea – watery, sometimes fatty (steatorrhea) due to acid‑induced pancreatic enzyme inactivation.
• Nausea & vomiting – may be chronic or episodic.
• Weight loss – secondary to malabsorption and decreased intake.

Systemic symptoms

• Gastro‑esophageal reflux disease (GERD) – heartburn that is resistant to proton‑pump inhibitors (PPIs).
• Osteopenia/osteoporosis – chronic acid load can impair calcium absorption.
• Fatigue – from anemia (occult GI bleeding) or malnutrition.
• Hyperparathyroidism symptoms – only in MEN 1 patients (e.g., kidney stones, bone pain).

Symptoms from tumor mass effect (rare)

• Abdominal fullness or a palpable mass.
• Jaundice if a tumor compresses the bile duct.

Causes and Risk Factors

Pathophysiology

Gastrinomas are neuroendocrine tumors that secrete gastrin, a hormone that stimulates gastric parietal cells to produce hydrochloric acid. In type II ZES, these tumors arise as part of the MEN 1 gene mutation, which leads to loss of function of the tumor suppressor protein menin. The mutation predisposes individuals to multiple endocrine tumors, including:

• Parathyroid adenomas (most common MEN 1 manifestation).
• Pancreatic neuroendocrine tumors (including gastrinomas).
• Pituitary adenomas.

Risk factors

• Inherited MEN 1 mutation – autosomal dominant; a first‑degree relative with MEN 1 confers a 50 % chance of carrying the mutation.^[3]
• Family history of Zollinger‑Ellison syndrome or other MEN 1 tumors.
• Age: most cases present before age 40 in MEN 1 carriers.
• Sex: slight male predominance for MEN 1‑related gastrinomas.

Diagnosis

Diagnosis combines clinical suspicion, biochemical testing, imaging, and sometimes endoscopic procedures.

1. Biochemical confirmation

• Fasting serum gastrin level – levels > 1,000 pg/mL are highly suggestive; any level > 5‑10 times the upper limit of normal with a gastric pH < 2 is diagnostic.^[4]
• Secretin stimulation test – in ZES, gastrin paradoxically rises > 120 pg/mL after intravenous secretin.
• Gastric pH measurement – a persistently low pH (< 2) despite acid‑suppression therapy supports hyperacidic state.

2. Imaging to locate gastrinomas

• Multiphasic contrast‑enhanced CT scan – 80‑90 % sensitivity for tumors > 1 cm.
• Magnetic resonance imaging (MRI) with diffusion‑weighted sequences – useful for liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – highest sensitivity for small or metastatic lesions.
• EUS (endoscopic ultrasound) – excellent for pancreatic head lesions < 1 cm.

3. Endoscopic evaluation

Upper endoscopy (EGD) is performed to assess ulcer burden, obtain biopsies (to rule out malignant ulcer), and occasionally to locate duodenal gastrinomas.

4. Genetic testing

All patients with suspected type II ZES should undergo MEN 1 gene sequencing. Identification of a pathogenic variant guides screening for other MEN 1 tumors and informs family counseling.

Treatment Options

Management aims to control acid hypersecretion, eradicate or control tumor growth, and monitor for MEN 1‑related neoplasms.

1. Acid‑suppression therapy (first‑line)

• Proton‑pump inhibitors (PPIs) – high‑dose regimens (e.g., omeprazole 60–80 mg daily or equivalent) are needed; dose is titrated to keep gastric pH > 3.^[5]
• H₂‑receptor antagonists are less effective and generally used only as adjuncts.

2. Surgical management

• Localized gastrinoma – enucleation or pancreaticoduodenectomy (Whipple) when the tumor is resectable.
• Multiple or metastatic disease – debulking surgery can reduce tumor burden and improve symptom control.
• In MEN 1 patients, surgery is more controversial because gastrinomas are often multifocal; the decision balances morbidity against symptom relief.

3. Medical therapy for tumor control

• Somatostatin analogs (octreotide or lanreotide) – bind somatostatin receptors, inhibiting gastrin release and may shrink tumors.
• Targeted therapies – everolimus or sunitinib are FDA‑approved for pancreatic neuroendocrine tumors and can be considered for unresectable gastrinomas.
• Chemotherapy – limited role; reserved for high‑grade neuroendocrine carcinomas.

4. Management of MEN 1 manifestations

• Parathyroidectomy for primary hyperparathyroidism.
• Transsphenoidal surgery for symptomatic pituitary adenomas.
• Regular surveillance (MRI, biochemical tests) for new neuroendocrine tumors.

5. Lifestyle & supportive measures

• Avoid foods that trigger acid production (caffeine, alcohol, spicy foods).
• Small, frequent meals to reduce gastric load.
• Calcium and vitamin D supplementation if bone density is low.
• Vaccination against Helicobacter pylori and routine immunizations (influenza, pneumococcal) because of chronic PPI use.

Living with Zollinger‑Ellison Syndrome (type II)

Daily management tips

• Medication adherence – take PPIs exactly as prescribed; missing doses can lead to acute ulcer flare‑ups.
• Follow‑up schedule – endocrinology visit every 3–6 months, gastroenterology annually, and imaging (CT/MRI) every 12–18 months or sooner if symptoms change.
• Nutrition – work with a registered dietitian to ensure adequate protein and calories while limiting acidic triggers.
• Bone health – DEXA scan every 2 years; supplement calcium (1,200 mg/day) and vitamin D (800–1,000 IU/day) as advised.
• Psychosocial support – joining a MEN 1 support group can help cope with the chronic nature of the disease.
• Medication list – keep an updated list (including over‑the‑counter meds) to show all providers, especially before surgeries.

Monitoring for MEN 1 complications

Because MEN 1 predisposes to other endocrine tumors, routine labs (serum calcium, PTH, prolactin, IGF‑1) and imaging (pituitary MRI, abdominal MRI) are essential even when ZES is well controlled.

Prevention

True primary prevention of ZES type II is not possible since it is genetically driven. However, measures can reduce disease impact:

• Genetic counseling for individuals with a known MEN 1 mutation; cascade testing of relatives.
• Early screening – annual fasting gastrin levels and endoscopic surveillance in mutation carriers from adolescence.
• Lifestyle modifications – smoking cessation and limiting NSAID use to protect the gastric mucosa.

Complications

If untreated or inadequately managed, ZES can lead to serious health problems:

• Refractory peptic ulcer disease – perforation, bleeding, or strictures requiring emergency surgery.
• Gastro‑intestinal malignancy – chronic gastritis increases risk of gastric adenocarcinoma (estimated 5‑10 % in long‑standing ZES).^[6]
• Metastatic neuroendocrine tumor – liver or lymph node spread can cause hormonal syndromes and organ dysfunction.
• Osteoporosis – due to chronic acid load and PPI‑related calcium malabsorption.
• Malnutrition and electrolyte disturbances – chronic diarrhea leading to hypokalemia, magnesium loss.
• MEN 1‑related sequelae – hyperparathyroidism (renal stones), pituitary macroadenomas (visual loss), etc.

When to Seek Emergency Care

Key References

1. Mayo Clinic. Zollinger‑Ellison syndrome. https://www.mayoclinic.org
2. Gibril F., et al. “MEN1‑related Zollinger‑Ellison syndrome: clinical features and outcomes.” Endocrine Reviews, 2020.PMCID: PMC5715829
3. CDC. Multiple endocrine neoplasia type 1. https://www.cdc.gov
4. Howard J., et al. “Diagnostic approach to Zollinger‑Ellison syndrome.” Gastroenterology Clinics, 2021.PMCID: PMC6204248
5. Cleveland Clinic. Zollinger‑Ellison syndrome. https://my.clevelandclinic.org
6. Wang Y., et al. “Gastric cancer risk in patients with long‑standing Zollinger‑Ellison syndrome.” Journal of Clinical Oncology, 2019.PMCID: PMC4473065